Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Kinase inhibitors like imatinib, dasatinib, and nilotinib have transformed cancer treatment, particularly for hematologic malignancies.
• While offering better tolerability than chemotherapy, these targeted therapies can cause significant systemic side effects.
• Mucocutaneous adverse events are the most common non-hematological toxicities associated with tyrosine kinase inhibitors.

Purpose of the Study:

• To analyze the histopathological features of cutaneous reactions induced by tyrosine kinase inhibitors.
• To propose a classification differentiating specific from non-specific skin side effects.
• To emphasize the importance of clinico-histological correlation for accurate diagnosis.

Main Methods:

• Review of existing literature on tyrosine kinase inhibitor-induced skin reactions.
• Analysis of clinical presentations and histopathological findings.
• Integration of personal clinical and pathological experience.

Main Results:

• Identification of distinct histopathological patterns associated with specific drug-induced reactions.
• Characterization of non-specific cutaneous reactions, often mimicking other dermatoses.
• Demonstration of the utility of histological examination in diagnosing these side effects.

Conclusions:

• Histopathological analysis is crucial for accurately diagnosing mucocutaneous side effects of tyrosine kinase inhibitors.
• Differentiating specific from non-specific reactions aids in appropriate patient management.
• Clinico-histological correlation is essential for optimal diagnosis and treatment of these adverse events.